Antihyperglycaemic therapy in elderly patients with type 2 diabetes: Potential role of incretin mimetics and DPP-4 inhibitors

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 154, 2007, Pages 29-37

  Mathieu, C ^a   Bollaerts, K ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; INCRETIN; INSULIN; METFORMIN; NATEGLINIDE; PLACEBO; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ABDOMINAL PAIN; ADD ON THERAPY; ADVERSE OUTCOME; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DIZZINESS; DOSE TIME EFFECT RELATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG MISUSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ELDERLY CARE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; GENETIC HETEROGENEITY; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MONOTHERAPY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT MONITORING; PHYSIOLOGY; POLYPHARMACY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; AGED; CHEMICALLY INDUCED DISORDER; DIABETES MELLITUS; MIDDLE AGED;

AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; MIDDLE AGED;

EID: 34250677349     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01437.x     Document Type: Review

References (70)

1. Selvin E, Coresh J, Brancati FL. The burden and treatment of diabetes in elderly individuals in the U.S. Diabetes Care 2006 29 : 2415 9.
2. Chiu KC, Lee NP, Cohan P, Chuang LM. Beta cell function declines with age in glucose tolerant Caucasians. Clin Endocrinol (Oxf) 2000 53 : 569 75.
3. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci 2001 56A : M5 13.
4. Fritsche A, Madaus A, Stefan N et al. Relationships among age, proinsulin conversion, and β-cell function in nondiabetic humans. Diabetes 2002 51 (Suppl. 1 S234 9.
5. Meneilly GS. Diabetes in the elderly. Med Clin North Am 2006 90 : 909 23.
6. Meneilly GS, Elliott T. Metabolic alterations in middle-aged and elderly obese patients with type 2 diabetes. Diabetes Care 1999 22 : 112 8.
7. Meneilly GS, Elahi D. Metabolic alterations in middle-aged and elderly lean patients with type 2 diabetes. Diabetes Care 2005 28 : 1498 9.
8. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994 43 : 403 10.
9. Matyka K, Evans M, Lomas J et al. Altered hierarchy of protective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 1997 20 : 135 41.
10. Bertoni AG, Hundley WG, Massing MW et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 2004 27 : 699 703.
11. Mayfield JA, Reiber GE, Maynard C et al. The epidemiology of lower-extremity disease in veterans with diabetes. Diabetes Care 2004 27 : B39 44.
12. US Centers for Disease Control and Prevention. Diabetes Public Health Resource: Data & Trends. Department of Health and Human Services, Centers for Disease Control and Prevention, 2004. Available from: http://www.cdc.gov/ diabetes/statistics/index.htm.
13. Young BA, Maynard C, Boyko EJ. Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003 26 : 2392 9.
14. Otter W, Kleybrink S, Doering W et al. Hospital outcome of acute myocardial infarction in patients with and without diabetes mellitus. Diabet Med 2004 21 : 183 7.
15. The Eye Diseases Prevalence Research Group. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004 122 : 552 63.
16. Meneilly GS, Cheung E, Tessier D et al. The effect of improved glycemic control on cognitive functions in the elderly patient with diabetes. J Gerontol 1993 48 : M117 21.
17. Kanaya AM, Barrett-Connor E, Gildengorin G, Yaffe K. Changes in cognitive function by glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study cohort. Arch Intern Med 2004 164 : 1327 33.
18. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996 44 : 751 5.
19. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997 157 : 1681 6.
20. Maciejewski ML, Maynard C. Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 2004 27 : B69 73.
21. Tuomilehto J, Rastenyte D, Birkenhager WH et al. for the Systolic Hypertension in Europe Trial Investigators. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med 1999 340 : 677 84.
22. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal Arch Intern Med 2000 160 : 2447 52.
23. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000 355 : 253 9.
24. Collins R, Armitage J, Parish S et al. and the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 361 : 2005 16.
25. Colhoun HM, Betteridge DJ, Durrington PN et al. for the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 364 : 685 96.
26. European Diabetes Working Party for Older People 2001-2004. Clinical Guidelines for Type 2 Diabetes Mellitus [Monograph on the Internet]. Available from: http://www.eugms.org/documents/clinicalguidelinediabetes.pdf.
27. Brown AF, Mangione CM, Saliba D, Sarkisian CA, for the California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 2003 51 (5 Suppl. guidelines S265 80.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
29. Muggeo M, Verlato G, Bonara E et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia 1995 38 : 672 9.
30. Andersson DK, Svardsudd K. Long-term glycemic control relates to mortality in type II diabetes. Diabetes Care 1995 18 : 1534 43.
31. Kuusisto J, Mykkanen L, Pyorala K, Laakso M. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994 43 : 960 7.
32. Gradman TJ, Laws A, Thompson LW, Reaven GM. Verbal learning and/or memory improves with glycemic control in older subjects with non-insulin-dependent diabetes mellitus. J Am Geriatr Soc 1993 41 : 1305 12.
33. Chelliah A, Burge MR. Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. Drugs Aging 2004 21 : 511 30.
34. American Diabetes Association. Standards of medical care in diabetes - 2006. Diabetes Care 2006 29 (Suppl. 1 S4 42.
35. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002 287 : 360 72.
36. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005 65 : 385 411.
37. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point Diabetologia. 2005 48 : 2454 9.
38. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
39. Del Prato S, Heine RJ, Keilson L et al. Treatment of patients over 64 years of age with type 2 diabetes: experience from nateglinide pooled database retrospective analysis. Diabetes Care 2003 26 : 2075 80.
40. The DECODE Study Group, for the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001 161 : 397 405.
41. Dormandy JA, Charbonnel B, Eckland DJA et al. for the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 366 : 1279 89.
42. Yki-Järvinen H. The PROactive study: some answers, many questions. Lancet 2005 366 : 1241 2.
43. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003 26 : 2929 40.
44. Deacon CF, Ahrén B, Holst JJ. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes Expert Opin Investig Drugs 2004 13 : 1091 102.
45. Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res 2004 36 : 747 54.
46. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006 368 : 1696 705.
47. Ahrén B. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties. Expert Opin Investig Drugs 2006 15 : 431 42.
48. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006 60 : 1454 70.
49. Meneilly GS, Greig N, Tildesley H et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care 2003 26 : 2835 41.
50. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002 87 : 1239 46.
51. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004 27 : 2628 35.
52. DeFronzo RA, Ratner RE, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005 28 : 1092 100.
53. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005 28 : 1083 91.
54. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006 8 : 436 47.
55. Byetta (Exenatide) Prescribing Information. San Diego, CA : Amylin Pharmaceuticals, Inc., 2007.
56. Heine RJ, Van Gaal LF, Johns D et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005 143 : 559 69.
57. Kim D, Macconell L, Zhuang D et al. Safety and effects of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Diabetes 2006 55 (Suppl. 1 116 (Abstract 487-P).
58. Nauck MA, Hompesch M, Filipczak R et al. and the N2211-1499 Study Group. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2006 114 : 417 23.
59. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. Diabetes 2006 55 (Suppl. 1 A27 8 (Abstract 115-OR).
60. Aschner P, Kipnes MS, Lunceford JK et al. for the Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006 29 : 2632 7.
61. Charbonnel B, Karasik A, Liu J et al. for the Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 29 : 2638 43.
62. Rosenstock J, Brazg R, Andryuk PJ et al. and Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 28 : 1556 68.
63. Januvia (Sitagliptin) Prescribing Information. Whitehouse Station, NJ : Merck & Co., Inc., 2006.
64. Dejager S, Lebeaut A, Couturier A, Schweizer A. Sustained reduction in HbA1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 2006 55 (Suppl. 1 A29 (Abstract 120-OR).
65. Nathwani A. The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Presented at American Diabetes Association - 66th Scientific Sessions, Washington, DC, 13 June, 2006.
66. Bosi E, Camisasca RP, Collober C et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007 30 : 890 5.
67. Foley JE, Dejager S, Chang I, Schweizer A. Effect of vildagliptin monotherapy on body weight in drug-naïve patients with type 2 diabetes (T2DM). Presented at the 19th World Diabetes Congress, Cape Town, South Africa, 3-7 December, 2006 (Abstract 826).
68. He YL, Sabo R, Wang Y et al. The influence of hepatic impairment on the pharmacokinetics of vildagliptin. Diabetes 2006 55 (Suppl. 1 A469 (Abstract 2024-PO).
69. He YL, Sabo R, Wang Y. Influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacol Ther 2006 79 : P63 (Abstract PIII-19).
70. Baron M, Dejager S, Chang I et al. Efficacy and tolerability of the DPP-4 inhibitor vildagliptin in drug-naïve patients with type 2 diabetes aged 65 and older. Diabet Med 2006 23 (Suppl. 4 295 (Abstract P805).